Producer
Takeda Plasma-Derived Therapies
Third-largest plasma fractionator (~29.5% market share); built through acquisitions of Shire (2019, $62B) and Baxalta; major hemophilia and immunology plasma portfolio; PDT (plasma-derived therapies) division is a standalone business unit
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Takeda Plasma-Derived Therapies supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Takeda Plasma-Derived Therapies makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Immunoglobulins
35%Hemophilia + Coagulation
25%Hereditary Angioedema (HAE)
20%Albumin + Other Plasma Proteins
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Origin2023
Takeda Pharmaceutical's $62 billion acquisition of Shire plc in 2019 was the largest overseas acquisition by a Japanese company in history — a bet by Japan's oldest major pharmaceutical company (founded 1781) that the global plasma-derived therapy market was the most defensible long-term pharmaceutical business. Shire had itself built its plasma position through a $5.9B acquisition of Baxter BioSciences in 2014, inheriting Baxter's legacy that included the development of ADVATE (recombinant Factor VIII, first approved 2003) — the dominant global Hemophilia A treatment. The acquisition chain: Baxter (US hospital products 1931) → Shire (UK specialty pharma 1986) → Takeda (Japan generics 1781). Japan's oldest pharmaceutical company now controls the most advanced hemophilia treatment, originated by a US hospital supply company, assembled by a British specialty pharma acquirer. The $62B Shire price was partly justified by the plasma business's near-monopoly economics: IVIG and Factor VIII markets have high barriers to entry, regulated source material, and patients with chronic lifetime treatment requirements.
Takeda Pharmaceutical Company ↗